In addition, Xu and colleagues performed a PB screen in melanoma cells and identified BRAF and CRAF as mediators of resistance to the BRAF inhibitor vemurafenib [62], recapitulating previous observations in human melanoma patients and cell lines treated with vemurafenib [63–65]. This evidence concerns the gene BRAF and melanoma.